The Globe and Mail reports in its Tuesday, Aug. 25, edition that in 2022 many pot companies saw declines of over 90 per cent. The Globe's guest columnist Philip MacKellar writes that insiders sold millions in stock. To mask their issues, many diluted existing shareholders significantly. Then in 2025 Aurora Cannabis and Cronos Group started looking interesting and were showing signs of stabilization. Cronos is a global player operating in Canada with recreational and medical products, and it supplies medical cannabis in Israel. It is expanding into Australia and Europe, currently acquiring CanAdelaar BV, the largest recreational cannabis provider in the Netherlands. Unlike many of its peers, Cronos has a lot going for it. In March, 2019, Altria invested $1.8-billion for a 45-per-cent stake (all figures U.S.). Since then, Cronos has been able to build out its business without worrying about debt or dilution. At the end of the last quarter, the balance sheet was a fortress with $797-million in cash and short-term investments, $1.18-billion in total assets and no debt. Though there has been some dilution since 2019, the top line has expanded faster, which means the dilution has been revenue per share accretive.